Mylan NV (MYL) Receives $47.77 Consensus Price Target from Analysts

Shares of Mylan NV (NASDAQ:MYL) have earned a consensus rating of “Buy” from the twenty-one analysts that are currently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating and thirteen have issued a buy rating on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $46.36.

Several analysts recently commented on MYL shares. Cowen restated a “hold” rating and set a $31.00 price target on shares of Mylan in a research report on Thursday, August 9th. Wells Fargo & Co restated a “hold” rating on shares of Mylan in a research report on Wednesday, July 25th. ValuEngine upgraded shares of Mylan from a “sell” rating to a “hold” rating in a research report on Tuesday, August 14th. Royal Bank of Canada dropped their price target on shares of Mylan from $51.00 to $50.00 and set a “buy” rating on the stock in a research report on Tuesday. Finally, Mizuho lowered shares of Mylan from a “buy” rating to a “neutral” rating in a research report on Friday, October 5th.

Shares of Mylan stock traded up $0.24 during trading on Monday, hitting $36.79. 1,276,649 shares of the company’s stock were exchanged, compared to its average volume of 6,361,761. The company has a debt-to-equity ratio of 1.10, a current ratio of 1.26 and a quick ratio of 0.77. Mylan has a 52-week low of $30.33 and a 52-week high of $47.82. The stock has a market cap of $18.78 billion, a PE ratio of 8.07, a price-to-earnings-growth ratio of 1.17 and a beta of 1.53.

Mylan (NASDAQ:MYL) last released its quarterly earnings results on Monday, November 5th. The company reported $1.25 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.19 by $0.06. The company had revenue of $2.86 billion for the quarter, compared to analyst estimates of $2.91 billion. Mylan had a net margin of 4.71% and a return on equity of 19.39%. The firm’s revenue was down 4.2% on a year-over-year basis. During the same quarter last year, the business earned $1.10 earnings per share. As a group, equities analysts expect that Mylan will post 4.61 EPS for the current year.

Several hedge funds and other institutional investors have recently made changes to their positions in MYL. Yorktown Management & Research Co Inc boosted its position in Mylan by 39.5% during the third quarter. Yorktown Management & Research Co Inc now owns 28,600 shares of the company’s stock worth $1,047,000 after acquiring an additional 8,100 shares during the last quarter. Norinchukin Bank The boosted its position in Mylan by 13.5% during the third quarter. Norinchukin Bank The now owns 66,314 shares of the company’s stock worth $2,427,000 after acquiring an additional 7,912 shares during the last quarter. Highstreet Asset Management Inc. boosted its position in Mylan by 54.5% during the third quarter. Highstreet Asset Management Inc. now owns 22,863 shares of the company’s stock worth $837,000 after acquiring an additional 8,066 shares during the last quarter. Toronto Dominion Bank boosted its position in Mylan by 56.6% during the third quarter. Toronto Dominion Bank now owns 577,599 shares of the company’s stock worth $21,136,000 after acquiring an additional 208,698 shares during the last quarter. Finally, SG Americas Securities LLC boosted its position in Mylan by 245.8% during the third quarter. SG Americas Securities LLC now owns 231,212 shares of the company’s stock worth $8,462,000 after acquiring an additional 164,352 shares during the last quarter. Institutional investors and hedge funds own 82.99% of the company’s stock.

Mylan Company Profile

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter (OTC) products worldwide. The company operates through three segments: North America, Europe, and Rest of World. It offers pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized, and cream or ointment forms.

Recommended Story: Relative Strength Index

Analyst Recommendations for Mylan (NASDAQ:MYL)

Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply